In 2024, Alliance Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Alliance Pharma has also provided a category-level breakdown for 10 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 0a | 0a | 2a | |
Total Scope 2 | ||||
Market-Based | 0a | 0a | 52a | |
Location-Based | 45.5a | 45.58a | 50a | |
Total Scope 3 | 38,957a | 49,991a | 45,603a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0a | 0a | 0.0099a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Alliance Pharma amounted to 45.5 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Alliance Pharma decreased by 0.18%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2024, the total Scope 1 emissions of Alliance Pharma were 0 metric tons of CO₂ equivalent (tCO₂e).a
Since 2022, Alliance Pharma's Scope 1 emissions have decreased by 100%, reflecting a declining long-term trend in Scope 1 emissions over time.a
In 2024, Alliance Pharma reported Scope 2 greenhouse gas (GHG) emissions of 0 tCO₂e using the market-based method and 45.5 tCO₂e using the location-based method.a
Since 2022, Alliance Pharma's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have remained relatively stable, indicating that Alliance Pharma's emissions have plateaued with no significant change in its energy consumption footprint.a
Compared to the previous year (2023), Alliance Pharma's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Alliance Pharma's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2024, Alliance Pharma reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2024, Alliance Pharma reported 38,957 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Alliance Pharma includes a breakdown across 10 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2024, Alliance Pharma reported total Scope 3 emissions of 38,957 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 99.59% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0.41% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2022, Alliance Pharma's Scope 3 emissions have decreased by 14.57%, reflecting a declining long-term trend in Scope 3 emissions over time.a
Compared to the previous year (2023), Alliance Pharma's Scope 3 emissions decreased by 22.07%, highlighting the company's efforts to lower indirect emissions from its value chain.a
In 2024, Alliance Pharma reported emissions for 10 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2024, the largest contributors to Alliance Pharma's Scope 3 emissions were:a
In 2022, Alliance Pharma reported Scope 1 greenhouse gas (GHG) emissions of 2 tCO₂e and total revenues of USD 202 millions. This translates into an emissions intensity of 0.01 tCO₂e per millions USD.a
In 2022, Alliance Pharma reported a Scope 1 emissions intensity of 0.01 tCO₂e per millions USD. Compared to the peer group median of 9.7, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2022, Alliance Pharma ranked 1 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Alliance Pharma among the top performers, with one of the lowest emissions intensities relative to peers.a
In 2024, Alliance Pharma reported a total carbon footprint of 39,002.5 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 22.05% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to Alliance Pharma's total carbon footprint was Scope 3 emissions, accounting for 99.88% of the company's total carbon footprint, followed by Scope 2 emissions at 0.12%.a